title: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
authors.forename: K
authors.initials: K
authors.lastname: Hiramatsu
authors.forename: H
authors.initials: H
authors.lastname: Hanaki
authors.forename: T
authors.initials: T
authors.lastname: Ino
authors.forename: K
authors.initials: K
authors.lastname: Yabuta
authors.forename: T
authors.initials: T
authors.lastname: Oguri
authors.forename: F C
authors.initials: FC
authors.lastname: Tenover
mesh_terms: D000617:Aminoglycosides; D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003982:Dibekacin / Q000031:analogs & derivatives / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D018633:Pulmonary Atresia / Q000150:complications / Q000601:surgery; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013407:Sulbactam / Q000627:therapeutic use; D014640:Vancomycin / Q000494:pharmacology* / Q000627:therapeutic use*; D014947:Wounds and Injuries / Q000382:microbiology
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D003982:Dibekacin; D014640:Vancomycin; D000667:Ampicillin; C031986:arbekacin; D013407:Sulbactam